Pages that link to "Q62028827"
Jump to navigation
Jump to search
The following pages link to DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma (Q62028827):
Displaying 50 items.
- Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax (Q24795118) (← links)
- Lymphoma Immunotherapy: Current Status (Q26782902) (← links)
- Therapeutic cancer vaccines: past, present, and future (Q26863283) (← links)
- Intensive treatment for multiple myeloma: where do we stand? (Q33709697) (← links)
- B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions (Q33776141) (← links)
- Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma (Q33814247) (← links)
- DNA vaccines against cancer: from genes to therapy. (Q33822028) (← links)
- Novel immunotherapies (Q33822677) (← links)
- The role of dendritic cells in the innate immune system. (Q33887435) (← links)
- Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help (Q33911670) (← links)
- DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza (Q33912001) (← links)
- Anti-idiotype vaccines for human follicular lymphoma (Q34002880) (← links)
- Biotherapy for lymphoma (Q34107861) (← links)
- How immunology is reshaping clinical disciplines: the example of haematology (Q34308986) (← links)
- Immunotherapy of multiple myeloma (Q34326534) (← links)
- The occurrence and significance of V gene mutations in B cell-derived human malignancy (Q34414672) (← links)
- Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? (Q34487427) (← links)
- An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide (Q34862104) (← links)
- Vaccination therapy for cutaneous T-cell lymphoma (Q35015875) (← links)
- Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells (Q35079386) (← links)
- Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody (Q35096289) (← links)
- Technical and regulatory hurdles for DNA vaccines (Q35143252) (← links)
- Immunotherapy for lymphomas (Q35169138) (← links)
- Vaccination strategies for lymphomas (Q35190692) (← links)
- Active immunotherapy in follicular lymphoma (Q35213344) (← links)
- Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model (Q35226109) (← links)
- Tumor vaccines. (Q35671699) (← links)
- Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma (Q35740264) (← links)
- Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines (Q35751104) (← links)
- DNA fusion gene vaccines against cancer: from the laboratory to the clinic. (Q35826392) (← links)
- DNA vaccines to attack cancer (Q35855143) (← links)
- Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study (Q35863376) (← links)
- Therapeutic idiotype vaccines for non-Hodgkin's lymphoma (Q35909323) (← links)
- Part II: Vaccines for haematological malignant disorders. (Q35974290) (← links)
- A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity (Q36221727) (← links)
- In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent (Q36375719) (← links)
- Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins (Q36386109) (← links)
- Polyclonal Antibody Production for Membrane Proteins via Genetic Immunization (Q36611210) (← links)
- Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity (Q36627887) (← links)
- Therapeutic vaccine for lymphoma (Q36746586) (← links)
- Recent advances and current challenges in tumor immunology and immunotherapy. (Q36765440) (← links)
- Anti-idiotype antibodies in cancer treatment (Q36832098) (← links)
- Trial watch: DNA vaccines for cancer therapy (Q36845824) (← links)
- Immune therapies (Q36998232) (← links)
- DNA vaccines: precision tools for activating effective immunity against cancer. (Q37064852) (← links)
- A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer (Q37078963) (← links)
- Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials (Q37142202) (← links)
- Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects (Q37170344) (← links)
- Therapeutic vaccines for non-Hodgkin B-cell lymphoma. (Q37270929) (← links)
- The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. (Q37729321) (← links)